SuperSpectra

Company Overview

Snapshot

Founded in May 2020 by Yevgeny Beiderman and Zeev Zalevsky, SuperSpectra operates with 1–10 employees. The company is currently in a Pre-Funding stage.

Business overview

SuperSpectra is a Health Tech & Life Sciences company focused on developing a noninvasive imaging device for the early detection and ongoing monitoring of Alzheimer's disease. Its core technology measures CSF A and tau quantitative results, providing high-accuracy, real-time imaging of Alzheimer's biomarkers. The device is designed to be ionizing radiation-free, pain-free, and risk-free, allowing for frequent testing. SuperSpectra operates within the medical devices sector, specifically diagnostics devices, and targets healthcare providers and patients.

Company Intelligence Q&A

What is SuperSpectra's primary focus?

SuperSpectra is developing a noninvasive imaging device for the early detection and degradation follow-up of Alzheimer's disease.

When was SuperSpectra founded?

SuperSpectra was founded in May 2020.

Who are the founders of SuperSpectra?

SuperSpectra was co-founded by Yevgeny Beiderman, who serves as CEO, and Zeev Zalevsky, who serves as CTO.

What technology does SuperSpectra utilize?

SuperSpectra's device provides high-accuracy quantitative measurement with real-time imaging of Alzheimer's disease biomarkers through noninvasive direct CSF analysis.

What is the current operational status of SuperSpectra?

SuperSpectra ceased to operate in September 2024.